Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

Medication paired with behavioral change support gives employers the opportunity to provide a more well-rounded approach to ...

Pediatric endocrinologist Dr. Casey Berman says GLP-1s may help children reduce their risk of developing serious health ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

More and more research indicates that GLP-1 analogues can have a blunting effect on addictions like drugs and alcohol. Drug ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data analysis.